| 2026/26/06 - 08:51 |
|
TRADING VIEW: PRICE TARGET 10.42€ - Strong Buy
|
www |
| 2026/21/06 - 18:51 |
|
MORNING STAR : ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M
|
www |
| 2026/21/06 - 18:45 |
|
MARKET SCREENER : Abionyx Pharma Raises EUR19 Million via Fully Subscribed Capital Increase
|
www |
| 2026/21/06 - 18:44 |
|
IDEAL INVESTISSEUR : Abionyx Pharma Announces a Capital Increase of €18.7M and the Preparation of a €10M Bond Issue with Fenja Capital
|
www |
| 2026/28/05 - 23:29 |
|
MARKET SCREENER : Abionyx Pharma launches capital increase
|
www |
| 2026/28/05 - 23:00 |
|
FINANZWIRE : ABIONYX Pharma Reports Stable First Quarter and Robust Financing for Future Growth
|
www |
| 2026/28/05 - 08:52 |
|
IDEAL INVESTISSEUR : Abionyx Pharma Announces a Capital Increase of €18.7
|
www |
| 2026/23/02 - 14:15 |
|
Les Echos : Abionyx dispose peut-être d'un futur blockbuster avec son traitement contre la septicémie
|
www |
| 2026/23/02 - 14:10 |
|
European Biotechnology : Abionyx Pharma with new CMO and Head of R&D
|
www |
| 2023/10/05 - 18:00 |
|
Contract Pharma - Abionyx Pharma Manufactures First Batch of CER-001 with Recombinant Human ApoA-I
|
pdf
|
| 2023/19/01 - 09:57 |
|
Scrip - Abionyx Looks To Next Steps As Renal Sepsis Candidate Succeeds At Phase IIa
|
pdf
|
| 2023/17/01 - 19:00 |
|
FierceBiotech - Abionyx hails success of bid to resurrect failed cholesterol drug—without dishing data to back up claims
|
www |
| 2023/17/01 - 10:00 |
|
European Biotechnology - Abionyx Pharma announces success in fighting sepsis-triggered AKI
|
pdf
|
| 2023/17/01 - 10:00 |
|
Clinical Trials Arena - Abionyx Pharma’s Phase IIa trial of CER-001 for AKI meets primary objective
|
pdf
|
| 2023/17/01 - 10:00 |
|
The Pharma Letter - Abionyx bullish on acute kidney injury drug’s prospects
|
pdf
|
| 2023/17/01 - 10:00 |
|
European Clinical Review - Potential treatment identified for septic patients
|
pdf
|
